OpportunityTitle: Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051).
GrantorContactEmailDescription: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
GrantorContactText: NIH OER Webmaster&lt;br/&gt;grantsinfo@nih.gov